MaxCyte Appoints Cynthia Collins to its Board of Directors

Core Insights - MaxCyte, Inc. has appointed Cynthia Collins as a non-executive director to its Board of Directors, effective October 14, 2024, increasing the total board members to 10 [1][2]. Group 1: Appointment Details - Cynthia Collins brings over 40 years of experience in biotechnology and cell and gene medicines, including her role as CEO of Editas Medicine, where she was involved in the first in-vivo gene modified therapy [2]. - Collins has held various leadership positions, including CEO of Human Longevity Inc. and General Electric Healthcare's Cell Therapy and Lab Businesses [2]. Group 2: Current Board Memberships - Currently, Collins serves on the boards of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics, Certara, DermTech, Draper Laboratory, and Panavance Therapeutics [3]. Group 3: Educational Background - Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana, and an MBA from The University of Chicago Booth School of Business [4]. Group 4: Company Overview - MaxCyte focuses on cell engineering to enhance the potential of cells for improving patient lives, with over 20 years of expertise in developing platforms for cell therapy [7]. - The ExPERT™ platform, based on Flow Electroporation® technology, supports the expanding cell therapy market from discovery to commercialization of next-generation cell-based medicines [7].